Skip to main content
Top
Published in: Diabetologia 8/2015

01-08-2015 | Article

Intestinal mTOR regulates GLP-1 production in mouse L cells

Authors: Geyang Xu, Ziru Li, Li Ding, Hong Tang, Song Guo, Hongbin Liang, Huadong Wang, Weizhen Zhang

Published in: Diabetologia | Issue 8/2015

Login to get access

Abstract

Aims/hypothesis

Glucagon-like peptide (GLP-1), an intestinal incretin produced in L cells through proglucagon processing, is released in response to meal intake. The intracellular mechanism by which L cells sense the organism energy level to coordinate the production of GLP-1 remains unclear. Mechanistic target of rapamycin (mTOR) is an intracellular fuel sensor critical for energy homeostasis. In this study, we investigated whether intestinal mTOR regulates GLP-1 production in L cells.

Methods

The effects of mTOR on GLP-1 production were examined in lean- or high-fat diet (HFD) induced diabetic C57/BL6, db/db, Neurog3-Tsc1 −/− mice, and STC-1 cells. GLP-1 expression was investigated by real-time PCR and western blotting. Plasma GLP-1 and insulin were detected by enzyme immunoassay and radioimmunoassay, respectively.

Results

Fasting downregulated mTOR activity, which was associated with a decrement of intestinal proglucagon and circulating GLP-1. Upon re-feeding, these alterations returned to the levels of fed animals. In HFD induced diabetic mice, ileal mTOR signalling, proglucagon and circulating GLP-1 were significantly decreased. Inhibition of mTOR signalling by rapamycin decreased levels of intestinal and plasma GLP-1 in both normal and diabetic mice. Activation of the intestinal mTOR signalling by l-leucine or Tsc1 gene deletion increased levels of intestinal proglucagon and plasma GLP-1. Overexpression of mTOR stimulated proglucagon promoter activity and GLP-1 production, whereas inhibition of mTOR activity by overexpression of tuberous sclerosis 1 (TSC1) or TSC2 decreased proglucagon promoter activity and GLP-1 production in STC-1 cells.

Conclusions/interpretation

mTOR may link energy supply with the production of GLP-1 in L cells.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880–11889PubMed Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880–11889PubMed
3.
go back to reference Drucker DJ, Mojsov S, Habener JF (1986) Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. J Biol Chem 261:9637–9643PubMed Drucker DJ, Mojsov S, Habener JF (1986) Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. J Biol Chem 261:9637–9643PubMed
4.
go back to reference Philippe J, Mojsov S, Drucker DJ, Habener JF (1986) Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas. Endocrinology 119:2833–2839PubMedCrossRef Philippe J, Mojsov S, Drucker DJ, Habener JF (1986) Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas. Endocrinology 119:2833–2839PubMedCrossRef
5.
go back to reference Elahi D, McAloon-Dyke M, Fukagawa NK et al (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63–74PubMedCrossRef Elahi D, McAloon-Dyke M, Fukagawa NK et al (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63–74PubMedCrossRef
6.
go back to reference Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719–2725PubMedCrossRef Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719–2725PubMedCrossRef
7.
go back to reference Jin T, Drucker DJ (1995) The proglucagon gene upstream enhancer contains positive and negative domains important for tissue specific proglucagon gene transcription. Mol Endocrinol 9:1306–1320PubMed Jin T, Drucker DJ (1995) The proglucagon gene upstream enhancer contains positive and negative domains important for tissue specific proglucagon gene transcription. Mol Endocrinol 9:1306–1320PubMed
9.
go back to reference Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464PubMedCrossRef Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464PubMedCrossRef
10.
go back to reference Mansour A, Hosseini S, Larijani B, Pajouhi M, Mohajeri-Tehrani MR (2013) Nutrients related to GLP-1 secretory responses. Nutrition 29:813–820PubMedCrossRef Mansour A, Hosseini S, Larijani B, Pajouhi M, Mohajeri-Tehrani MR (2013) Nutrients related to GLP-1 secretory responses. Nutrition 29:813–820PubMedCrossRef
11.
go back to reference Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294:1102–1105PubMedCrossRef Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294:1102–1105PubMedCrossRef
12.
go back to reference Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19–24PubMedCrossRef Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19–24PubMedCrossRef
13.
go back to reference Um SH, Frigerio F, Watanabe M et al (2007) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205CrossRef Um SH, Frigerio F, Watanabe M et al (2007) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205CrossRef
15.
go back to reference Xu G, Li Y, An W et al (2009) Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake. Endocrinology 150:3637–3644PubMedCentralPubMedCrossRef Xu G, Li Y, An W et al (2009) Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake. Endocrinology 150:3637–3644PubMedCentralPubMedCrossRef
16.
17.
19.
go back to reference Li D, Han L, Li Y, Zhao J, He P, Zhang W (2014) Neurogenin 3–directed Cre deletion of Tsc1 gene causes pancreatic acinar carcinoma. Neoplasia 16:909–917PubMedCentralPubMedCrossRef Li D, Han L, Li Y, Zhao J, He P, Zhang W (2014) Neurogenin 3–directed Cre deletion of Tsc1 gene causes pancreatic acinar carcinoma. Neoplasia 16:909–917PubMedCentralPubMedCrossRef
20.
go back to reference Lee YC, Asa SL, Drucker DJ (1992) Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem 267:10705–10708PubMed Lee YC, Asa SL, Drucker DJ (1992) Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem 267:10705–10708PubMed
21.
go back to reference Mortensen K, Christensen LL, Holst JJ, Orskov C (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114:189–196PubMedCrossRef Mortensen K, Christensen LL, Holst JJ, Orskov C (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114:189–196PubMedCrossRef
22.
go back to reference Eissele R, Göke R, Willemer S et al (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Investig 22:283–291CrossRef Eissele R, Göke R, Willemer S et al (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Investig 22:283–291CrossRef
23.
go back to reference Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety–effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206–1214PubMedCrossRef Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety–effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206–1214PubMedCrossRef
24.
go back to reference Schonhoff SE, Giel-Moloney M, Leiter AB (2004) Minireview: development and differentiation of gut endocrine cells. Endocrinology 145:2639–2644PubMedCrossRef Schonhoff SE, Giel-Moloney M, Leiter AB (2004) Minireview: development and differentiation of gut endocrine cells. Endocrinology 145:2639–2644PubMedCrossRef
25.
go back to reference Fraenkel M, Ketzinel-Gilad M, Ariav Y et al (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945–957PubMedCrossRef Fraenkel M, Ketzinel-Gilad M, Ariav Y et al (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945–957PubMedCrossRef
26.
go back to reference Barlow AD, Nicholson ML, Herbert TP (2013) Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes 62:2674–2682PubMedCentralPubMedCrossRef Barlow AD, Nicholson ML, Herbert TP (2013) Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes 62:2674–2682PubMedCentralPubMedCrossRef
27.
go back to reference Yang J, Dolinger M, Ritaccio G et al (2012) Leucine stimulates insulin secretion via down-regulation of surface expression of adrenergic α2A receptor through the mTOR (mammalian target of rapamycin) pathway: implication in new-onset diabetes in renal transplantation. J Biol Chem 287:24795–24806PubMedCentralPubMedCrossRef Yang J, Dolinger M, Ritaccio G et al (2012) Leucine stimulates insulin secretion via down-regulation of surface expression of adrenergic α2A receptor through the mTOR (mammalian target of rapamycin) pathway: implication in new-onset diabetes in renal transplantation. J Biol Chem 287:24795–24806PubMedCentralPubMedCrossRef
28.
go back to reference Fuhrmann A, Lopes P, Sereno J et al (2014) Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol 88:216–228PubMedCrossRef Fuhrmann A, Lopes P, Sereno J et al (2014) Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol 88:216–228PubMedCrossRef
29.
go back to reference Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36:741–744PubMedCrossRef Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36:741–744PubMedCrossRef
30.
go back to reference Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47PubMedCrossRef Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47PubMedCrossRef
31.
go back to reference Kolterman OG, Buse JB, Fineman MS et al (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082–3089PubMedCrossRef Kolterman OG, Buse JB, Fineman MS et al (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082–3089PubMedCrossRef
32.
go back to reference Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW (2012) Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 97:121–131PubMedCentralPubMedCrossRef Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW (2012) Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 97:121–131PubMedCentralPubMedCrossRef
33.
go back to reference Bjerre Knudsen L, Madsen LW, Andersen S et al (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473–1486PubMedCrossRef Bjerre Knudsen L, Madsen LW, Andersen S et al (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473–1486PubMedCrossRef
34.
go back to reference Parks M, Rosebraugh C (2010) Weighing risks and benefits of liraglutide–the FDA’s review of a new antidiabetic therapy. N Engl J Med 9:774–777CrossRef Parks M, Rosebraugh C (2010) Weighing risks and benefits of liraglutide–the FDA’s review of a new antidiabetic therapy. N Engl J Med 9:774–777CrossRef
35.
go back to reference Deacon CF, Johnsen AH, Host JJ (2002) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957 Deacon CF, Johnsen AH, Host JJ (2002) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957
36.
go back to reference Knudsen LB, Pridal L (1996) Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429–435PubMedCrossRef Knudsen LB, Pridal L (1996) Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429–435PubMedCrossRef
37.
go back to reference Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35:992–1019PubMedCrossRef Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35:992–1019PubMedCrossRef
38.
go back to reference Charbonnel B, Karasik A, Liu J, Wu M, Meininger G (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638–2643PubMedCrossRef Charbonnel B, Karasik A, Liu J, Wu M, Meininger G (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638–2643PubMedCrossRef
39.
go back to reference Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, de Williams-Herman (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632–2637PubMedCrossRef Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, de Williams-Herman (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632–2637PubMedCrossRef
40.
go back to reference Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150–156PubMedCentralPubMedCrossRef Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150–156PubMedCentralPubMedCrossRef
41.
go back to reference Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58:1604–1615PubMedCentralPubMedCrossRef Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58:1604–1615PubMedCentralPubMedCrossRef
42.
go back to reference Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595–2604PubMedCentralPubMedCrossRef Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595–2604PubMedCentralPubMedCrossRef
Metadata
Title
Intestinal mTOR regulates GLP-1 production in mouse L cells
Authors
Geyang Xu
Ziru Li
Li Ding
Hong Tang
Song Guo
Hongbin Liang
Huadong Wang
Weizhen Zhang
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3632-6

Other articles of this Issue 8/2015

Diabetologia 8/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.